Compare Novo Nordisk A/S (NVO) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard S&P 500 ETF — how do they compare? Novo Nordisk A/S trades at $46.26 (market cap $207.85B), while Vanguard S&P 500 ETF trades at $709.62. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | VOO | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $710.71 |
52-Week Low | $35.29 | $580.93 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
VOO, the Vanguard S&P 500 ETF, trades at $710.19, down slightly by 0.06% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is near its pivot point of $709, with immediate resistance at $711. Recent news highlights the S&P 500 at record highs, with JPMorgan raising its year-end target to 8,000, citing strong earnings and AI-driven growth, while some caution emerges from overbought signals and high valuations.
The outlook remains positive given institutional bullishness and AI tailwinds, but risks include market overvaluation, potential pullbacks from overbought conditions, and sensitivity to inflation data. Long-term investors may benefit from dollar-cost averaging, though short-term volatility warrants caution amid elevated sentiment and technical indicators signaling near-term exhaustion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
